Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $15.6 billion and adjusted earnings of $1.72 per share, ...

Looking at the universe of stocks we cover at Dividend Channel, in trading on Thursday, shares of Merck & Co Inc (Symbol: MRK) were yielding above the 3% mark based on its quarterly dividend ...

We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Merck & Co., Inc. is among the most undervalued stocks. On December 12, 2025, Morgan Stanley analyst Terence Flynn ...

Merck & Co., Inc. (NYSE:MRK) is an American multinational pharmaceutical company. Concerns are growing, however, as its top-selling cancer drug, Keytruda, starts losing patent protections in 2028.

Merck presents a bullish investment case with strong valuation, improving grades, and a well-supported, growing dividend. MRK's technical setup is positive: price trades above its 30-week EMA, ...

Members of Congress have traded $MRK stock 15 times in the past 6 months. Of those trades, 6 have been purchases and 9 have been sales. Here’s a breakdown of recent ...

Merck stock gapped up on news regarding its c19 drug, molnupiravir - namely the drug's phase 3 trial interim results. The market seems to be prematurely pricing in the approval of the drug as well as ...